The UK boasts immense potential in life sciences, supported by its robust health system infrastructure, renowned academic institutions, growing biotech industry and established global reputation for clinical innovation.
These assets can be the backbone of the Labour government’s mission to deliver better healthcare in Britain, and enhancing patient access to innovative medical treatments must be a top priority.
However, if we’re serious about advancing the health of the nation and ensuring timely access to new treatments, the way we value medicines must change.
Check out the rest of the feature here
